How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,976 results for

Serum Ferritin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

5641. Clinical Evaluation of Iron Treatment Efficiency Among Non-anemic But Iron-deficient Female Blood Donors

Posted : February 15, 2013 Last Update Posted : February 15, 2013 Sponsor: University of Lausanne Collaborator: Pierre Fabre Laboratories Information provided by (Responsible Party): Bernard Favrat, University of Lausanne Study Details Study Description Go to Brief Summary: The purpose of this study is to determine the subjective response of iron substitution (Tardyferon®) on fatigue in women blood donors with a mean serum ferritin < 30ng/ml and to assess variation of ferritin and hemoglobin after (...) the subjective response of iron substitution (Tardyferon®) on fatigue in women blood donors with a mean serum ferritin < 30ng/ml and to assess variation of ferritin and hemoglobin after a blood donation. We will measure blood count, ferritin level and C-reactive protein at the time of the blood donation and then after a week, a month and 3 months. A week after the blood donation, donors with a ferritin level <30 ng/ml and hemoglobin > 120g/l (non anaemic) will be included in the study and randomised. A one

2008 Clinical Trials

5642. The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality

is not evaluable for storage iron, transferrin saturation must be > 20 % and serum ferritin not less than 50 ng/ml). Use of haematopoietic growth factors within 7 days of the first day of study drug treatment. Use of G-CSF is permitted. Concurrent use of erythropoietin Chronic use (>2 weeks) of greater than physiologic doses of a corticosteroid agent (dose equivalent to >10 mg/day of prednisolone) within 28 days of the first day of study lenalidomide treatment. Use of experimental or standard drugs (i.e (...) The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information

2009 Clinical Trials

5643. A Pilot Study of Chronic Red Blood Cell Transfusion in Sickle Cell Disease-Associated Pulmonary Hypertension

A Pilot Study of Chronic Red Blood Cell Transfusion in Sickle Cell Disease-Associated Pulmonary Hypertension A Pilot Study of Chronic Red Blood Cell Transfusion in Sickle Cell Disease-Associated Pulmonary Hypertension - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. A Pilot Study of Chronic Red Blood Cell Transfusion in Sickle Cell Disease-Associated Pulmonary Hypertension The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00850369 Recruitment Status : Withdrawn (Slow accrual onto the study) First Posted

2009 Clinical Trials

5644. MRI Screening for Patients With Myelodysplastic Syndrome (MDS), Who Have Received Multiple Red Blood Cell Transfusions

patients with MDS who have received at least 50 units of Red Blood Cell Transfusions. Serum ferritin > 1,000 Written informed consent by the patient. Exclusion Criteria: Contraindication to MRI, including cardiac pacemaker, brain aneurysm clip, implanted neurostimulator, insulin pump, cochlear implant, metal slivers in the eyes, intrauterine device or any other MRI incompatible metal implants or intractable claustrophobia. Contacts and Locations Go to Information from the National Library of Medicine (...) MRI Screening for Patients With Myelodysplastic Syndrome (MDS), Who Have Received Multiple Red Blood Cell Transfusions MRI Screening for Patients With Myelodysplastic Syndrome (MDS), Who Have Received Multiple Red Blood Cell Transfusions - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2008 Clinical Trials

5645. Oral supplementation with NaFeEDTA reduces blood lead in postmenopausal but not premenopausal Korean women with anemia. (Abstract)

group. When age and baseline Hb levels were adjusted for, PbB concentrations decreased by 0.10 and 0.31 microg/dL in the PRE-M and POST-M groups, respectively, and the results were significant using a multivariate model (P = 0.016). Iron status determined by zinc protoporphyrin, transferrin saturation, and Hb improved significantly in both groups, but serum ferritin decreased significantly in the POST-M women (P < 0.001), with no change in the PRE-M group.After 6 mo of supplementation (...) Oral supplementation with NaFeEDTA reduces blood lead in postmenopausal but not premenopausal Korean women with anemia. The objective was to evaluate the effect of iron supplementation for 6 mo on blood lead (PbB) concentration in populations of premenopausal (PRE-M) and postmenopausal (POST-M) Korean women.We conducted a community intervention trial in Asan, Republic of Korea. Of the 137 enrolled women with hemoglobin (Hb) levels lower than 12 g/dL, 37 were PRE-M and 100 were POST-M. Each

2008 Nutrition (Burbank, Los Angeles County, Calif.)

5646. Efficacy and Safety Study of Magnesium Iron Hydroxycarbonate for the Reduction of High Blood Phosphate in Hemodialysis Patients

, megacolon, or mechanical obstruction. A significant illness in the 4 weeks before screening. Taking medication prescribed for seizures. A history of haemochromatosis. A history of high serum ferritin concentration of ≥ 1000ng/ml (excluding transient, treatment-induced ferritin elevation). A history of dysphagia or swallowing disorders that might limit the subject's ability to swallow study medication in the opinion of the investigator. Female subjects who are lactating or pregnant. Women of childbearing (...) Efficacy and Safety Study of Magnesium Iron Hydroxycarbonate for the Reduction of High Blood Phosphate in Hemodialysis Patients Efficacy and Safety Study of Magnesium Iron Hydroxycarbonate for the Reduction of High Blood Phosphate in Hemodialysis Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached

2006 Clinical Trials

5647. Iron Replacement in Blood Donors

Update Posted: July 2, 2017 Last Verified: March 1, 2012 Keywords provided by National Institutes of Health Clinical Center (CC): Hemoglobin Iron Supplementation Donor Retention Iron Stores Ferritin Transferrin Saturation Healthy Volunteer HV Blood Donors Additional relevant MeSH terms: Layout table for MeSH terms Anemia, Iron-Deficiency Anemia, Hypochromic Anemia Hematologic Diseases Iron Metabolism Disorders Metabolic Diseases Iron Trace Elements Micronutrients Nutrients Growth Substances (...) Iron Replacement in Blood Donors Iron Replacement in Blood Donors - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Iron Replacement in Blood Donors The safety and scientific validity of this study

2006 Clinical Trials

5648. Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)

days. In the MPA group, each menstrual cycle starts on the 1st bleeding day (withdrawal bleeding) and lasts until the last non-bleeding day before next withdrawal bleeding starts. Percent Change in Hemoglobin [ Time Frame: Baseline and up to 6 months ] Percent Change in Hematocrit [ Time Frame: Baseline and up to 6 months ] Percent Change in Serum Ferritin [ Time Frame: Baseline and up to 6 months ] Percentage of Patients With Improvement in the Investigator Global Assessment Scale [ Time Frame: Up (...) Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS) Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information

2006 Clinical Trials

5649. Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload

, unacceptable toxicities and/or documented poor response to locally approved iron chelators despite proper compliance History of at least 20 blood transfusions (equivalent to 100 mL/kg of packed red blood cells (PRBC]) Serum ferritin value greater than or equal to 1000 µg/L Ability to comply with all study-related procedures, medications, and evaluations Exclusion Criteria: Ongoing treatment with another iron chelator (Any other iron chelation therapy must be discontinued at least 24 hours prior to study (...) ) leading to study drug interruption or discontinuation. Note: only treatment emergent AEs are summarized. Secondary Outcome Measures : The Change in Serum Ferritin Values From Baseline Through Completion of the Study [ Time Frame: Baseline to end of study (Median exposure time to drug was approximately 30 weeks; Maximum exposure was 104 weeks) ] The number of participants with Improvement, No Change or Worsening in Serum ferritin category levels at the end of the study compared to baseline. Serum

2005 Clinical Trials

5650. Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia

Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration (...) or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia The safety and scientific validity of this study is the responsibility of the study sponsor

2009 Clinical Trials

5651. Effect of blood transfusions on the outcome of very low body weight preterm infants under two different transfusion criteria. Full Text available with Trip Pro

2006, 36 VLBW preterm babies were admitted to our neonatal intensive care unit and were randomly allocated to the "restrictive" (n= 19) or "liberal" (n= 17) criteria for PRBC transfusion. Complete blood count (CBC) was examined at admission and 30 days later. Reticulocyte counts, serum iron and ferritin were examined and compared with the clinical outcomes.Infants in the liberal group received a larger PRBC transfusion volume compared with the restrictive group over 30 days (41.7+/-20.1 vs. 27.2 (...) Effect of blood transfusions on the outcome of very low body weight preterm infants under two different transfusion criteria. Multiple packed red blood cell (PRBC) transfusions in very low birth weight (VLBW) prematurity have been suggested to be a risk factor for the development of retinopathy of prematurity (ROP) or for chronic lung disease (CLD). The purpose of this study was to examine the effect of PRBC transfusions on the outcome of VLBW prematurity.In total, between July 2005 and June

2009 Pediatrics and neonatology Controlled trial quality: uncertain

5652. Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. Full Text available with Trip Pro

/reduced glutathione ratio (P < 0.05). In summary, intravenous iron sucrose provokes oxidative damage to peripheral blood lymphocyte DNA in hemodialysis patients, especially among those with high levels of ferritin. (...) Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. Patients undergoing maintenance hemodialysis have elevated markers of oxidative stress, but the reasons for this are not fully understood. Intravenous administration of iron, which many of these patients receive, may provoke the generation of bioactive iron, which enhances oxidative stress and lipid peroxidation. In this study, 110 hemodialysis patients were randomly assigned

2008 Journal of the American Society of Nephrology : JASN Controlled trial quality: uncertain

5653. Short-term ferrous sulfate supplementation in female blood donors. (Abstract)

for possible repeat donation. Each volunteer was given 21 tablets of 150 mg of ferrous sulfate or placebo to be taken three times daily for 1 week after each blood donation. Their hemoglobin (Hb) concentration, hematocrit (Hct), serum ferritin, total iron-binding capacity (TIBC), and percent saturation of the TIBC were tested throughout the course of the study.The group taking ferrous sulfate showed no significant difference between the mean initial and final result for any of the values other than Hb (...) values, whereas there was a significant decline in mean Hb, Hct, serum iron, serum ferritin, and percent saturation in the group taking placebo. Hb concentrations declined significantly in both groups; however, it was more severe in the placebo group when compared to the ferrous sulfate group. The relative risk of iron deficiency in placebo group was 3.6 (95% confidence interval = 1.73-7.74).The results indicate that supplementation therapy can be considered as one of the strategies to promote safe

2008 Transfusion Controlled trial quality: uncertain

5654. Red blood cell metallothionein as an indicator of zinc status during pregnancy. Full Text available with Trip Pro

(86 who received daily supplements containing 60 mg of iron and 250 microg of folic acid and 72 whose supplements also contained 25 mg of zinc). In addition, we measured plasma and urinary zinc concentrations, hemoglobin and serum ferritin, and, on a limited sample, RBC zinc and placental MT.RBCMT increased during pregnancy, and levels in the cord blood approximated maternal values at 36 wk. Only RBC zinc at 36 wk differed by supplement type (P < 0.05). Increases in RBCMT over pregnancy were (...) Red blood cell metallothionein as an indicator of zinc status during pregnancy. We describe the levels and patterns of change in red blood cell (RBC) metallothionein (MT) during pregnancy and the neonate and relate RBCMT to other indicators of zinc and iron status.As part of a double-masked controlled trial of prenatal zinc supplementation among 242 Peruvian pregnant women, we determined RBCMT at enrollment (10-16 wk), at 28 and 36 wk of gestation, and in the cord blood at delivery in 158 women

2008 Nutrition (Burbank, Los Angeles County, Calif.) Controlled trial quality: uncertain

5655. Pre-operative oral iron supplementation reduces blood transfusion in colorectal surgery - a prospective, randomised, controlled trial. Full Text available with Trip Pro

at pound1500). At admission, ferritin in the iron-treated group had risen significantly from 40 microg/l (range, 15-222 microg/l) to 73 microg/l (range, 27-386 microg/l; P = 0.0036; 95% CI 46.53-10.57).Oral ferrous sulphate given pre-operatively in patients undergoing colorectal surgery offers a simple, inexpensive method of reducing blood transfusions. (...) Pre-operative oral iron supplementation reduces blood transfusion in colorectal surgery - a prospective, randomised, controlled trial. Allogeneic blood transfusion confers a risk to the recipient. Recent trials in colorectal surgery have shown that the most significant factors predicting blood transfusion are pre-operative haemoglobin, operative blood loss and presence of a transfusion protocol. We report a randomised, controlled trial of oral ferrous sulphate 200 mg TDS for 2 weeks' pre

2007 Annals of the Royal College of Surgeons of England Controlled trial quality: uncertain

5656. Iron fortification reduces blood lead levels in children in Bangalore, India. (Abstract)

and compliance monitored.Hemoglobin, serum ferritin, C-reactive protein, transferrin receptor, zinc protoporphyrin, and blood lead concentrations were measured.The prevalence of iron deficiency was significantly reduced in the iron group (from 70% to 28%) compared with the control group (76% to 55%). There was a significant decrease in median blood lead concentration in the iron group compared with the control group. The prevalence of blood lead levels > or =10 microg/dL was significantly reduced in the iron (...) Iron fortification reduces blood lead levels in children in Bangalore, India. Chronic lead poisoning and iron deficiency are concentrated in urban children from lower socioeconomic strata, and both impair neurocognitive development. Our study objective was to determine if iron fortification reduces blood lead levels in urban, lead-exposed, iron-deficient children in Bangalore, India.A randomized, double-blind, controlled school-based feeding trial was done in 5- to 13-year-old iron-deficient

2006 Pediatrics Controlled trial quality: predicted high

5657. Early umbilical cord clamping contributes to elevated blood lead levels among infants with higher lead exposure. (Abstract)

status was analyzed in maternal, placental, and 6-month infant blood samples. Baseline maternal lead exposure data and infant feeding data at 2, 4, and 6 months were collected.In the total sample, maternal blood lead concentration, infant ferritin, and breast-feeding practices predicted infant blood lead concentration. Among infants with higher placental blood lead concentration and breast-fed infants not receiving any iron-fortified formula or milk at 6 months, early clamping increased infant blood (...) Early umbilical cord clamping contributes to elevated blood lead levels among infants with higher lead exposure. To investigate whether infant iron status, modified by umbilical cord clamping time and infant feeding mode, affected infant blood lead concentration at 6 months of age.Participants were a subset of women and their infants randomized to receive early (10 seconds) or delayed (2 minutes) umbilical cord clamping and were monitored to 6 months postpartum in Mexico City. Iron and lead

2007 The Journal of pediatrics Controlled trial quality: uncertain

5658. Iron stores, blood donation, and insulin sensitivity and secretion. Full Text available with Trip Pro

], decreased insulin secretion [186 (82) vs 401.7 (254) mIU/L x min; P <0.0001], and significantly lower iron stores [serum ferritin, 101.5 (74) vs 162 (100) microg/L; P = 0.017] than nondonors, but the 2 groups had similar blood hematocrits and blood hemoglobin concentrations.Blood donation is simultaneously associated with increased insulin sensitivity and decreased iron stores. Stored iron seems to impact negatively on insulin action even in healthy people, and not just in classic pathologic conditions (...) Iron stores, blood donation, and insulin sensitivity and secretion. Epidemiologists have observed that blood donation is associated with decreased risk of type 2 diabetes and cardiovascular disease.We investigated the relationship between iron stores and insulin sensitivity, after controlling for known confounding factors, and compared insulin sensitivity between blood donors and individuals who had never donated blood (nondonors). In 181 men, insulin sensitivity and insulin secretion were

2005 Clinical Chemistry

5659. Cord blood zinc protoporphyrin/heme ratio in minority neonates at risk for iron deficiency. (Abstract)

Cord blood zinc protoporphyrin/heme ratio in minority neonates at risk for iron deficiency. We measured cord blood zinc protoporphyrin/heme (ZnPP/H) and plasma ferritin in healthy African-American and Hispanic newborns, matched by gestation with Caucasian newborns. In these at-risk minorities, cord ZnPP/H was higher and plasma ferritin lower, supporting the feasibility of screening newborns at-risk for iron deficiency at birth.

2008 Journal of Pediatrics

5660. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. (Abstract)

< 0.05) that distinguished patients with systemic JIA from healthy controls (n = 30) were identified. Clustering analysis indicated that expression patterns correlated with serum ferritin levels. Three main clusters distinguished systemic JIA patients with highly elevated ferritin levels (including those with subclinical macrophage activation syndrome) from those with normal or only moderately elevated ferritin levels. The first cluster comprised genes involved in the synthesis of hemoglobins (...) Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Systemic juvenile idiopathic arthritis (JIA) is frequently associated with the development of macrophage activation syndrome. This study was undertaken to better understand the relationship between systemic JIA and macrophage activation syndrome.Gene expression profiles were examined in 17

2007 Arthritis and Rheumatism

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>